[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593280":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":30,"locations":36,"responsibleParty":55,"collaborators":29,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":29,"enrollmentInfo":67,"targetDuration":29,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":84,"whyStopped":29,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Hospital Dr Sotero del Rio","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Amino acid interventión group","EXPERIMENTAL","Patients over 18 years old scheduled to undergo liver transplantation who are expected to have an ICU stay of at least 24 hours in the immediate postoperative period, regardless of the cause of liver failure and whether it was stable liver failure or acute on chronic liver failure. They will receive an intravenous infusion of a mixture of amino acids that includes L-arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after the surgery.",[13,14],"Drug: Amino acid solution","Drug: Amino Acid infusion",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Amino acid solution","Adult patients scheduled for orthotopic liver transplant to receive an intravenous infusion of a mixture of amino acids including L arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after surgery; the infusion will begin in the operating room prior to the start of the surgery, will be administered through an exclusive lumen of a central venous catheter (CVC) immediately after the CVC is in place; the infusion will continue when the patient is in the intensive care unit (ICU); as soon as the patient begins enteral nutrition, the infusion will be reduced to meet the dose of 2 g per kg of protein intake per day up to a maximum of 100 g daily, until completing 72 H of infusion. The Control Group consists of previously transplanted patients at this institution who did not receive this type of therapy.",[9],[22],"l arginine",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Amino Acid infusion","adult patients scheduled for orthotopic liver transplant to receive an intravenous infusion of a mixture of amino acids including L arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after surgery; the infusion will begin in the operating room prior to the start of the surgery, will be administered through an exclusive lumen of a central venous catheter (CVC) immediately after the CVC is in place; the infusion will continue when the patient is in the intensive care unit (ICU); as soon as the patient begins enteral nutrition, the infusion will be reduced to meet the dose of 2 g per kg of protein intake per day up to a maximum of 100 g daily, until completing 72 H of infusion. The Control Group consists of previously transplanted patients at this institution who did not receive this type of therapy.",[9],[28],"l arginina",null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"GUILLERMO A MOLINA, SPECIALIST IN CRITICAL CARE","CONTACT","988258412","guillermo.molina@sotero.cl",[37],{"facility":38,"status":29,"city":39,"state":40,"zip":29,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Hospital Sotero Del Rio","Santiago","Puente ALTO","Chile","CL",{"type":44,"coordinates":45},"Point",[46,47],-70.64827,-33.45694,{"lat":47,"lon":46},[50,52],{"name":51,"role":33,"phone":29,"phoneExt":29,"email":29},"GUILLERMO A MOLINA",{"name":53,"role":54,"phone":29,"phoneExt":29,"email":29},"GUILLERMO A MOLINA MANCERO, CRITICAL CARE SPECIALIST","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"GUILLERMO MOLINA MANCERO","SPECIALIST IN INTENSIVE CARE MEDICINE","100593280","perioperative-use-of-amino-acids-in-recipients-of-orthotopic-liver-transplantation-as-a-renal-protective-factor-100593280",false,"NCT07004387","Perioperative Use of Amino Acids in Recipients of Orthotopic Liver Transplantation as a Renal Protective Factor","PAATHO","Inclusion Criteria:\n\n* All patients assigned to receive a liver transplant will be evaluated for eligibility.\n* Patients over 18 years old scheduled for a liver transplant will be considered eligible if it is expected that they will have an ICU stay of at least 24 hours in the immediate postoperative period, regardless of the cause of liver failure and whether it was stable liver failure or acute on chronic liver failure.\n* They must have a baseline measurement of serum creatinine that does not exceed 30 days prior to surgery or can be taken before the transplant surgery.\n\nExclusion Criteria:\n\n* Patients under 18 years old will be excluded.\n* Patients with a need for chronic hemodialysis, patients with chronic kidney disease with an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 square meters of body surface area calculated by the Cockcroft-Gault equation.\n* Patients with acute renal failure requiring acute intermittent or continuous renal replacement therapy during the hospitalization for surgery.\n* Patients who refuse informed consent to participate in the study.","ALL","18 Years",{"count":68,"type":69},90,"ESTIMATED","INTERVENTIONAL",[72],"NA","Orthotopic liver transplantation is the definitive treatment for end-stage liver failure, with renal failure being an important complication of this procedure that has implications for long- and short-term prognosis, affecting ICU stay and hospitalization time. Several studies have suggested that intravenous amino acids, particularly L-arginine, may have protective effects on renal function due to increased renal blood flow, which could be explained by enhanced production of nitric oxide among other mechanisms that are still unclear. In this context, we developed the hypothesis that the infusion of an amino acid solution in the perioperative period could reduce the incidence of acute renal failure in this group of patients; for this, we conducted a monocentric, analytical, prospective, interventional pilot study comparing standard treatment (in historically transplanted patients) with a group of patients who were administered amino acids in the perioperative period, considering that this medication is low-cost and has practically minimal side effects.",[75,76,77],"Hepatic Failure","Liver Transplant","Renal Failure, Acute",[79,80,81,82,83],"liver transplant","renal failiure","amino acids","surguery","ICU","NOT_YET_RECRUITING","2025-05-27",{"date":87,"type":88},"2025-06-04","ACTUAL",{"date":85,"type":69},{"date":91,"type":69},"2026-09-30",{"name":5,"class":6},1]